

CAMB/IMM 6090: Vaccines & Immune Therapy Fall 2022

Time: 3:30 PM – 5:30 PM

Location: The Wistar Institute

Grossman Auditorium / GoToMeeting

Instructors: David Weiner, Paul Offit, Stanley Plotkin, Emilio Emini

Class Coordinator: Jeneice Hubert

V-Virtual Lecture / IP – In Person Lecture

<u>Date</u>	<u>Title</u>	<u>Lecturer</u>
Sept 14	The Role of antibodies in RSV prevention: The story of Nirsevimab	Tonya Villafana – AstraZeneca IP
	Passive Immunization with Suvratroxumab To Prevent S. Aureus Ventilator Associated Pneumonias	Mark Esser – AstraZeneca IP
Sept 15	B Cells, Antibodies, & Humoral Immune Response	David Allman – PENN IP
Sept 21	Correlates of Protection by Vaccines	Stanley Plotkin – Emeritus V Professor of Pediatrics
	Welcome/Vaccine History	David Weiner – Wistar IP
Sept 22	The Enigma of Dengue Vaccine Development	Kevin Russell – Merck IP
Sep 28	Vaccines for Infectious Diseases that Disproportionately Impact the Poor	Penny Heaton – Janssen
Sept 29	Cellular Immune Responses	Michael Betts – PENN IP
Oct 12	Cure-HIV	Luis Montaner – Wistar IP
Oct 13	Meningococcal Vaccines	Samuel J Crowe – CDC

JENEICE HUBERT

Weiner Lab Coordinator

Assistant to: Dr. David B. Weiner

P (215) 898-0381 E jhubert@wistar.org

<u>Date</u>	<u>Title</u>	<u>Lecturer</u>
Oct 19	Adoptive Cell Therapy for Cancer	Marco Ruella – UPENN IP
Oct 20	Rotavirus Vaccines	Paul Offit – CHOP IP
	Novel technologies to develop AMR vaccines	Sanjay Phogat – GSK IP
Oct 26	The Challenge of Successful Vaccine Development & Delivery	Emilio Emini – Bill & Melinda Gates Medical Research Institute IP
Oct 27	Vaccines against AMR pathogens	Sanjay Phogat – GSK IP
	Required Reading - Books Distributed Final Exam Review & Topics	David Weiner – Wistar IP
Nov 2	Structure-based Vaccines	Daniel Kulp – Wistar IP
	Pneumococcal Conjugate	Wendy Watson – Pfizer
Nov 3	Vaccine Safety	Paul Offit – CHOP IP
	Developing a SARS CoV-2 Vaccine at Warp Speed	Paul Offit – CHOP IP
Nov 9	Overview of the Advisory Committee on Immunization practices (ACIP) Example: Hepatitis A Disease and Vaccines	Michelle Goveia – Merck IP
Nov 10	Development of a COVID-19 mRNA Vaccine At Lightspeed	Kathrin Jansen – Pfizer V

<u>Date</u>	<u>Title</u>	<u>Lecturer</u>
Nov 16	Developing a heterologous prime-boost Ebola vaccine – challenges and opportunities	Ruxandra Draghia-Akli – Janssen IP
Nov 17	Regulatory Considerations for Preventative Vaccines	Doran Fink – FDA V
	Understanding Vaccine Safety After Licensure	Meghna Alimchandani – FDA V
Nov 30	<i>TBP</i>	Drew Weissman – UPENN
	Personalized Cancer Vaccines	Gerald Linette – UPENN
Dec 1	Developing vaccines against emerging infections outside of the usual regulatory framework	Gary Kobinger – V Galveston National Laboratory
Dec 7	Final Exams	<i>TBD</i>